Alnylam Pharmaceuticals Inc Financial Flexibility Index
Alnylam Pharmaceuticals Inc financial flexibility index. Alnylam Pharmaceuticals Inc (ALNY) has a Financial Flexibility Index of 0.04x as of December 2025. Free cash flow of $186.85 Million (operating CF $163.56 Million minus capex $23.29 Million) represents 0% of total liabilities ($4.18 Billion). See Alnylam Pharmaceuticals Inc free cash flow efficiency to measure how efficiently the company converts operating cash flow to free cash.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Financial Flexibility Index of Alnylam Pharmaceuticals Inc (2002–2025)
Financial flexibility index of Alnylam Pharmaceuticals Inc from 2002 to 2025. Historical Financial Flexibility Index trend for Alnylam Pharmaceuticals Inc across 24 annual periods. Check ALNY cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
Alnylam Pharmaceuticals Inc Financial Flexibility Index by Year (2002–2025)
Alnylam Pharmaceuticals Inc financial flexibility index by year from 2002 to 2025. Year-by-year free cash flow to debt coverage for Alnylam Pharmaceuticals Inc. For the full cash flow conversion analysis, see ALNY cash flow metrics.
| Year | Flexibility Index | Free Cash Flow (USD) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.14x | $582.78 Million | $524.08 Million | $4.18 Billion | ▲ +2142.2% |
| 2024 | 0.01x | $25.96 Million | $-8.31 Million | $4.17 Billion | ▼ -84.9% |
| 2023 | 0.04x | $166.37 Million | $104.16 Million | $4.05 Billion | ▲ +132.4% |
| 2022 | -0.13x | $-469.21 Million | $-541.27 Million | $3.70 Billion | ▲ +31.6% |
| 2021 | -0.19x | $-565.32 Million | $-641.69 Million | $3.06 Billion | ▲ +18.8% |
| 2020 | -0.23x | $-544.60 Million | $-614.96 Million | $2.39 Billion | ▼ -57.6% |
| 2019 | -0.14x | $-138.27 Million | $-278.43 Million | $956.44 Million | ▲ +90.9% |
| 2018 | -1.60x | $-435.73 Million | $-562.62 Million | $272.84 Million | ▼ -30.9% |
| 2017 | -1.22x | $-278.58 Million | $-382.79 Million | $228.30 Million | ▼ -71.9% |
| 2016 | -0.71x | $-243.14 Million | $-307.70 Million | $342.59 Million | ▲ +50.9% |
| 2015 | -1.45x | $-176.19 Million | $-189.14 Million | $121.80 Million | ▼ -32.3% |
| 2014 | -1.09x | $-156.68 Million | $-165.64 Million | $143.33 Million | ▼ -153.9% |
| 2013 | -0.43x | $-64.65 Million | $-68.66 Million | $150.18 Million | ▲ +38.4% |
| 2012 | -0.70x | $-107.26 Million | $-115.61 Million | $153.47 Million | ▼ -33.6% |
| 2011 | -0.52x | $-85.78 Million | $-87.07 Million | $163.92 Million | ▼ -54.5% |
| 2010 | -0.34x | $-79.61 Million | $-84.34 Million | $235.03 Million | ▼ -52.9% |
| 2009 | -0.22x | $-67.20 Million | $-72.14 Million | $303.42 Million | ▼ -202.4% |
| 2008 | 0.22x | $76.25 Million | $65.49 Million | $352.55 Million | ▼ -68.8% |
| 2007 | 0.69x | $204.31 Million | $196.52 Million | $294.62 Million | ▲ +237.1% |
| 2006 | -0.51x | $-19.64 Million | $-24.63 Million | $38.83 Million | ▼ -27.2% |
| 2005 | -0.40x | $-14.54 Million | $-16.48 Million | $36.57 Million | ▲ +24.9% |
| 2004 | -0.53x | $-10.56 Million | $-19.57 Million | $19.96 Million | ▼ -237.3% |
| 2003 | -0.16x | $-9.71 Million | $-12.83 Million | $61.89 Million | ▼ -354.8% |
| 2002 | -0.03x | $-716.00K | $-1.28 Million | $20.76 Million | — |